• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedema.

作者信息

Chakraborty Debdulal, Mondal Soumen, Parachuri Nikulaa, Kumar Nilesh, Sharma Ashish

机构信息

Disha Eye Hosiptal, Kolkata, West Bengal, India.

Sankara eye Hospital, Coimbatore, Tamil Nadu, India.

出版信息

Eye (Lond). 2022 Feb;36(2):358-360. doi: 10.1038/s41433-021-01816-3. Epub 2021 Oct 13.

DOI:10.1038/s41433-021-01816-3
PMID:34645970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8807620/
Abstract
摘要

相似文献

1
Brolucizumab-early experience with early extended interval regime in chronic centre involved diabetic macular oedema.布罗卢izumab——慢性中心采用早期延长给药间隔方案治疗糖尿病性黄斑水肿的早期经验。
Eye (Lond). 2022 Feb;36(2):358-360. doi: 10.1038/s41433-021-01816-3. Epub 2021 Oct 13.
2
Diabetic macular oedema in 2011: what are the options for refractory cystic oedema?2011年糖尿病性黄斑水肿：难治性囊性水肿有哪些治疗选择？
Clin Exp Ophthalmol. 2011 Sep-Oct;39(7):595-7. doi: 10.1111/j.1442-9071.2011.02662.x.
3
Combined therapy with intravitreal bevacizumab and posterior subtenon triamcinolone acetonide injection in diabetic macular oedema.玻璃体腔内注射贝伐单抗联合后Tenon囊下注射曲安奈德治疗糖尿病性黄斑水肿
Acta Ophthalmol. 2014 Nov;92(7):e589-90. doi: 10.1111/aos.12420. Epub 2014 May 27.
4
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.雀鹰和风筝研究：布罗鲁单抗治疗糖尿病性黄斑水肿两项III期关键试验的52周结果
Am J Ophthalmol. 2022 Jun;238:157-172. doi: 10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14.
5
A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE).一项评估布罗鲁单抗与阿柏西普治疗糖尿病性黄斑水肿所致视力损害患者的疗效和安全性的随机、双盲、多中心、III期研究（KITE）。
Klin Monbl Augenheilkd. 2020 Apr;237(4):450-453. doi: 10.1055/a-1101-9126. Epub 2020 Mar 4.
6
Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes.糖尿病性黄斑水肿患者血管内皮生长因子基因多态性的患病率及其与抗血管内皮生长因子治疗效果的相关性。
Clin Exp Ophthalmol. 2014 May-Jun;42(4):369-78. doi: 10.1111/ceo.12182. Epub 2013 Sep 24.
7
Intravitreal ranibizumab for diabetic macular oedema: 1-year experiences in a clinical setting.玻璃体内注射雷珠单抗治疗糖尿病性黄斑水肿：临床环境下的1年经验
Acta Ophthalmol. 2013 May;91(3):e243-4. doi: 10.1111/aos.12014. Epub 2012 Dec 31.
8
Faricimab (Vabysmo) for age-related macular degeneration and diabetic macular edema.法西单抗（Vabysmo）用于治疗年龄相关性黄斑变性和糖尿病性黄斑水肿。
Med Lett Drugs Ther. 2022 Mar 21;64(1646):45-46.
9
Short-term efficacy of intravitreal triamcinolone acetonide for bevacizumab-resistant diabetic macular oedema.玻璃体内注射曲安奈德治疗抗贝伐单抗的糖尿病性黄斑水肿的短期疗效
Acta Ophthalmol. 2015 Mar;93(2):e178-9. doi: 10.1111/aos.12504. Epub 2014 Jul 10.
10
Aflibercept (Eylea) and diabetic macular oedema. A first-choice VEGF inhibitor in case of marked visual loss.阿柏西普（阿瓦斯汀）与糖尿病性黄斑水肿。在出现明显视力丧失的情况下的首选血管内皮生长因子抑制剂。
Prescrire Int. 2015 Sep;24(163):207.

引用本文的文献

1
Brolucizumab efficacy and safety single-arm descriptive trial in patients with persistent diabetic macular edema (BEST study): protocol for a single-centre, open-label, single-arm clinical trial in China.布罗鲁单抗治疗持续性糖尿病黄斑水肿患者的疗效和安全性单臂描述性试验（BEST研究）：中国一项单中心、开放标签、单臂临床试验方案
BMJ Open. 2025 Jul 28;15(7):e099551. doi: 10.1136/bmjopen-2025-099551.
2
Brolucizumab for the Treatment of Diabetic Macular Edema: An Optical Coherence Tomography-Based Analysis.布罗鲁单抗治疗糖尿病性黄斑水肿：基于光学相干断层扫描的分析
Diagnostics (Basel). 2024 Dec 19;14(24):2858. doi: 10.3390/diagnostics14242858.
3
Real-World Experience with Brolucizumab Compared to Aflibercept in Treatment-Naïve and Therapy-Refractory Patients with Diabetic Macular Edema.在初治和治疗难治性糖尿病性黄斑水肿患者中，布罗鲁单抗与阿柏西普对比的真实世界经验。
J Clin Med. 2024 Mar 21;13(6):1819. doi: 10.3390/jcm13061819.
4
Real-World Experience With Brolucizumab 6 mg for Diabetic Macular Edema.6毫克布罗鲁单抗治疗糖尿病性黄斑水肿的真实世界经验
Cureus. 2024 Jan 12;16(1):e52176. doi: 10.7759/cureus.52176. eCollection 2024 Jan.
5
Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis.抗血管内皮生长因子药物玻璃体腔内注射治疗新生血管性年龄相关性黄斑变性的按需治疗策略：一项荟萃分析。
Eye (Lond). 2023 Oct;37(14):2855-2863. doi: 10.1038/s41433-023-02439-6. Epub 2023 Mar 1.
6
Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series.玻璃体内注射布罗珠单抗治疗视网膜中央静脉阻塞所致顽固性黄斑水肿：一项小型病例系列研究
Case Rep Ophthalmol. 2022 Nov 17;13(3):921-928. doi: 10.1159/000526710. eCollection 2022 Sep-Dec.
7
Brolucizumab for the Treatment of Degenerative Macular Conditions: A Review of Clinical Studies.Brolucizumab 治疗退行性黄斑病变：临床研究综述。
Drug Des Devel Ther. 2022 Aug 9;16:2659-2680. doi: 10.2147/DDDT.S378450. eCollection 2022.

本文引用的文献

1
Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study.布罗鲁单抗相关的视网膜血管炎伴雷珠单抗再次治疗后病情加重：一项临床病理病例研究。
Am J Ophthalmol Case Rep. 2020 Nov 10;20:100989. doi: 10.1016/j.ajoc.2020.100989. eCollection 2020 Dec.